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ABSTRACT Ertapenem is a carbapenem antibiotic with activity against Mycobacte-
rium tuberculosis. Dose simulations in a hollow-ﬁber infection model showed that
2,000 mg once daily is an appropriate dose to be tested in clinical studies. Before
using this dose in a phase II study, the aim of this prospective pharmacokinetic
study was to conﬁrm the pharmacokinetics of 2,000 mg once daily in tuberculosis
(TB) patients. Twelve TB patients received a single intravenous dose of 2,000 mg er-
tapenem as a 30-min infusion. Blood samples were collected at 0, 0.5, 1, 2, 3, 4, 8,
12, and 24 h postadministration. Drug concentrations were measured using a vali-
dated liquid chromatography-tandem mass spectrometry assay. A large interindi-
vidual variation in the pharmacokinetics of ertapenem was observed. The median
(interquartile range) area under the plasma concentration-time curve to inﬁnity
(AUC0–∞) was 2,032 (1,751 to 2,346) mg · h/liter, the intercompartmental clear-
ance (CL12) was 1.941 (0.979 to 2.817) liters/h, and the volume of distribution in the
central compartment (V1) was 1.514 (1.064 to 2.210) liters. A more than dose-
proportional increase in AUC was observed compared to results reported for 1,000
mg ertapenem in multidrug-resistant TB patients. Based on a MIC of 1.0 mg/liter, 11
out of 12 patients would have reached the target value of unbound drug exceeding
the MIC over 40% of the time (f40% TMIC). In conclusion, this study shows that
2,000 mg ertapenem once daily in TB patients reached the expected f40% TMIC
for most of the patients, and exploration in a phase 2 study can be advocated.
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The World Health Organization (WHO) estimated that there were approximately600,000 new cases of rifampin-resistant tuberculosis (RR-TB), of which 490,000 were
multidrug-resistant tuberculosis (MDR-TB), in 2016 (1). MDR-TB means resistance to at
least two ﬁrst-line anti-TB drugs, namely rifampin and isoniazid. MDR-TB is treated with
a combination of second-line anti-TB drugs, which are more toxic and less effective
than the ﬁrst-line anti-TB drugs (1, 2). In addition, MDR-TB treatment lasts up to 20
months, in contrast to ﬁrst-line anti-TB treatment, which takes 6 months (1). A shorter
treatment duration of 9 to 12 months recommended by the WHO in May 2016 is only
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suitable for the relatively small subset of patients with pulmonary MDR- or RR-TB that
is not resistant to ﬂuoroquinolones, second-line injectables, or pyrazinamide (1). The
success rate of MDR-TB treatment is approximately 50% worldwide, which calls for
improvement (1). There is a need for new treatment options, especially for patients with
additional resistance to two important classes of second-line drugs, ﬂuoroquinolones
and injectable aminoglycosides or capreomycin, referred to as extensively drug-
resistant TB (XDR-TB) (1, 3).
Ertapenem is a carbapenem antimicrobial drug that belongs to the group of
-lactam antibiotics (4). Ertapenem is not included in the MDR-TB treatment guidelines,
in contrast to two other carbapenems, i.e., imipenem and meropenem (5, 6). The
efﬁcacy of carbapenems against Mycobacterium tuberculosis is attributable to the
inactivation of L,D-transpeptidases, which are responsible forM. tuberculosis peptidogly-
can cross-linking. The efﬁcacy of treatment with ertapenem is expected to be related to
the free, unbound concentration based on the debated inability of protein-bound
ertapenem to distribute to the infection site and bind to the target bacterial penicillin-
binding protein (7–9). An early bactericidal activity study, including both free and
bound ertapenem measurements, could be of help to answer the question of whether
unbound or total drug determines the efﬁcacy of ertapenem. The antibacterial activity
of carbapenems is mainly determined by the time that the plasma concentration
exceeds the MIC (TMIC) (10–12). Based on previous studies in mice and in a hollow-
ﬁber model, it is expected that free 40% time above the MIC (f40% TMIC) is the most
important pharmacodynamic (PD) parameter (12, 13). M. tuberculosis can inactivate
ertapenem with the enzyme -lactamase, and for this reason ertapenem needs to be
combined with the -lactamase inhibitor clavulanic acid (4, 5, 14).
Carbapenems are generally well tolerated. A systematic study showed that less than
15% of all adverse events that occur during treatment that contained carbapenems,
together with other anti-TB drugs, were attributable to carbapenems (15). Like for the
older carbapenems, adverse events associated with ertapenem are often transient and
mild (16). In contrast to imipenem and meropenem, ertapenem only needs to be
administered once daily due to its longer half-life (4). Based on the in vitro activity and
its long half-life, ertapenem is a promising drug in the treatment of MDR- and XDR-TB
(4, 13, 15).
A hollow-ﬁber model is an in vitro model to simulate the human pharmacokinetics
with a cartridge containing M. tuberculosis, mimicking the target site of infection. The
European Medicines Agency has accepted hollow-ﬁber system models to be used in
dose ﬁnding and regimen selection for the treatment of M. tuberculosis (17). Addition-
ally, it could be used to deﬁne pharmacokinetic/pharmacodynamic (PK/PD) targets and
show target attainment when sufﬁcient data are available on human pharmacokinetics
of anti-TB drugs (13).
In this study, we want to verify the hypothesis of van Rijn et al. that 2,000 mg
ertapenem would be the most suitable dose for the treatment of TB (13). Therefore, the
primary goals of this study were to determine the pharmacokinetics of 2,000 mg
ertapenem to verify the hypothesis, compare the exposure of 2,000 mg ertapenem in
TB patients to the exposure of 200 mg · h/liter used in the hollow-ﬁber model study,
and to determine the f40% TMIC (13).
RESULTS
Patients. In total, 12 culture-conﬁrmed patients with drug-susceptible TB received
a single intravenous infusion of 2,000 mg ertapenem. Patients were mostly men (92%)
with a median (interquartile range [IQR]) age of 36 (26 to 42) years and a BMI of 20.4
(18.5 to 23.7) kg/m2 (Table 1). Ten out of 12 patients had predominantly pulmonary TB,
one patient had TB colitis besides pulmonary TB, and one patient had TB peritonitis.
One patient experienced nausea after receiving 2,000 mg ertapenem. The patient
did not vomit. Another patient experienced pain at the infusion site. This occurred 3 h
after infusion. Afterwards the drip was placed in the other arm, where the pain also
occurred after approximately 5 h.
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Pharmacokinetics. The pharmacokinetics of all patients is shown in Table 2. There
is a large interindividual variation in the pharmacokinetics, especially in the area under
the plasma concentration-time curve (AUC) (Fig. 1), which could be caused by a large
variation in intercompartmental clearance (CL12) and volume of distribution (V).
Free 40% time above the MIC. Based on a MIC of 0.5 mg/liter and a percentage of
unbound ertapenem of 5%, all patients exceeded the minimum f40% TMIC (range,
10.32 to 22.88 h). This means that all TB patients would have a sufﬁcient therapeutic
concentration if the MIC was 0.5 mg/liter or less. If the MIC was 1.0 mg/liter, 11 out of
12 patients would have exceeded the minimum of f40% TMIC (range, 8.08 to 20.96
h). At a MIC of 2.0 mg/liter, 7 out of 12 patients exceeded the minimum of f40% TMIC
(range, 5.62 to 14.88 h). The percentage of patients achieving f40% TMIC at various
MIC values is shown in Fig. 2.
DISCUSSION
To our knowledge, this is the ﬁrst study showing the pharmacokinetics of 2,000 mg
ertapenem in TB patients. A dose of 2,000 mg ertapenem had a better ability to reach
the f40%TMIC, the PK/PD parameter related to microbial kill (13). The dose was based
on the results from the study of van Rijn et al., who showed in a hollow-ﬁber model that
TABLE 1 Patient characteristics
Parameter
Value for drug-susceptible TB
patientsa (n  12)




Age (yr) 36 (26–42)
wt (kg) 65.0 (56.8–77.3)
BMI (kg/m2) 20.4 (18.5–23.7)
BSA (m2) 1.80 (1.67–1.96)
Serum creatinine at baseline (mmol/liter) 68 (59–75)






aData are expressed as medians (interquartile ranges) unless stated otherwise.
TABLE 2 Pharmacokinetic parameters of 2,000 mg ertapenem in tuberculosis patients
Pharmacokinetic parametera Median (IQR)
AUC0–∞ (h · mg/liter) 2032 (1751–2346)
CL12 (liters/h) 1.941 (0.979–2.817)
V1 (liters) 1.514 (1.064–2.210)
V2 (liters) 2.984 (1.912–3.428)
Vss (liters) 4.560 (3.857–5.160)
k10 (/h) 0.677 (0.539–0.863)
k12 (/h) 1.690 (0.482–2.666)
k21 (/h) 0.718 (0.530–0.863)
t1/2 1 (h) 0.225 (0.162–0.519)
t1/2 2 (h) 3.859 (3.620–4.301)
MRT (h) 3.991 (3.840–5.494)
MIT (h) 0.296 (0.250–0.342)
aAUC0–∞, area under the concentration-time curve from 0 h to inﬁnity; CL12, intercompartmental clearance;
V1, volume of distribution of the central compartment; V2, volume of distribution in the peripheral
compartment; Vss, volume of distribution at steady-state; k12 and k21, ﬁrst-order intercompartmental transfer
rate constants between the central and peripheral compartments; k10, elimination rate constant; t1/2 1 and
2, distribution and elimination half-lives; MRT, mean resident time; MIT, mean input time.
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2,000 mg ertapenem might be more effective in the treatment of M. tuberculosis than
1,000 mg (18). Another study, however, with healthy young volunteers, has been
published on the pharmacokinetics of 2,000 mg (19). The results from the study of
Majumdar et al. were used for comparison with the results from this study (19). The
patient characteristics of the healthy volunteers were signiﬁcantly different from those
of our TB patients, except for the distribution of males and females in both studies. The
AUC from time zero to inﬁnity (AUC0–∞) and peak concentration (Cmax) were shown to
be twice as high in TB patients as in healthy volunteers (19). The higher AUC0–∞ could
be due to the lower plasma clearance in TB patients, which was 33 times lower than
that in healthy volunteers. Also, the volume of distribution in TB patients was half that
in healthy volunteers, explaining the higher plasma concentration of ertapenem (20).
As can be seen from the results, the volume of distribution in the central compart-
ment (V1) is lower than the total plasma volume of around 3 liters. This shows that there
was incomplete distribution at the time of taking the ﬁrst plasma sample, which may
be caused by slow distribution of ertapenem after an infusion of 30 min. Because of this
incomplete distribution, the V1 value cannot be calculated correctly. Another explana-
FIG 1 Plasma-concentration time curve for all 12 patients receiving 2,000 mg ertapenem.
FIG 2 Percent target attainment for patients receiving 2,000 mg ertapenem at various MICs. 40% TMIC,
40% of time above the MIC.
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tion for the high Cmax is the sampling from the same arm. In order to eliminate this
possibility, we took samples from two of the patients at two time points from the other
arm, but this gave the same analytical results, contributing to the assumption that
ertapenem had incomplete distribution immediately after administration. There were
no speciﬁc differences in patient characteristics or treatment that could explain this
slow distribution.
In the study of healthy volunteers, it was shown that there was a slightly less than
dose-proportional increase in AUC over a dose range of 0.5 to 3 g ertapenem (19). This
is due to saturation of plasma protein binding, which causes the unbound fraction of
ertapenem to increase at higher plasma concentrations. Comparing the studies with
1,000 mg and 2,000 mg ertapenem in TB patients, 2,000 mg showed a more than
dose-proportional increase in AUC, since the mean AUC is more than three times as
high for 2,000 mg as it is for 1,000 mg (18). The clearance is higher for 1,000 mg than
for 2,000 mg, but the volume of distribution is not signiﬁcantly different in this case
(18). The only difference between the two patient groups, except for the dose of
ertapenem given, is the age of the patients (18).
A dose of 2,000 mg ertapenem in TB patients showed nonlinear pharmacokinetic
behavior, which is thought to be caused by saturation of the major metabolic pathway
according to the signiﬁcantly reduced clearance (21). The major metabolic pathway in
the case of ertapenem has been shown to be the formation of the beta-lactam
ring-open metabolite by dehydropeptidase-1, located in the renal tubules. Around 37%
of ertapenem is metabolized to the beta-lactam ring-open metabolite and excreted by
the kidneys (9). In earlier studies it was shown that the renal clearance of unbound
ertapenem can exceed the glomerular ﬁltration rate, which is hypothesized to be the
result of tubular secretion. The mean renal clearance of unbound ertapenem was 207
ml/min, which is higher than the creatinine clearance, indicating that ertapenem
undergoes glomerular ﬁltration and net tubular secretion (7). A similar phenomenon of
saturation of renal clearance is also seen with piperacillin (22).
Additionally, the volume of distribution at steady state (Vss) is lower than expected.
The Vss of 2,000 mg ertapenem was shown to be around 9.5 liters for healthy volunteers
(19); however, we found a Vss of 4.560 liters in TB patients. One reason for this could be
the difference in body composition, which was shown to be the case previously (19).
Another possibility is that it was difﬁcult to estimate the Vss correctly due to nonlinear
pharmacokinetic behavior (23).
A study by Chen et al. showed that obese patients had lower AUCs than normal-
weight patients (24). Our TB patients had a signiﬁcantly lower BMI than the healthy
volunteers, and this could have explained the higher AUC. The PK variability of 1,000 as
well as 2,000 mg ertapenem in healthy volunteers was also lower than that in TB
patients, which could be due to the disease state (18, 19). Three patients received 2,000
mg ertapenem during a 1-h infusion instead of half an hour, as was stated in the
protocol. However, the PK of these patients did not signiﬁcantly differ from those of
the other patients, as the volume of distribution was between 5.321 and 5.808 and the
clearance was between 0.813 and 1.295. Therefore, the longer infusion time is thought
not to have inﬂuenced the pharmacokinetic results.
The bacteriostatic target of f40% TMIC was reached in all patients at a MIC of 0.5
mg/liter, 92% of the patients at a MIC of 1 mg/liter, and 58% at a MIC of 2 mg/liter.
Target attainment was considerably higher in this study compared with what was
observed in the study of 1,000 mg ertapenem in MDR-TB patients, where only 2 out of
12 patients reached f40% TMIC at a MIC of 1 mg/liter (18). Van Rijn et al. used an AUC
of 200 mg · h/liter to simulate the pharmacokinetics and determine the target attain-
ment; however, in our study a median AUC0–∞ of 2,032 mg · h/liter was found (13). In
that study, around 63% of the patients would achieve f40% TMIC at a MIC of 2
mg/liter. In the current study, we show that 58% of the patients reached the target
value at a MIC of 2 mg/liter. We have used the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) values for the MIC of ertapenem instead of determining
the MIC distributions. This is due to the fact that the EUCAST-approved methods
PK of 2,000 mg Ertapenem in TB Patients Antimicrobial Agents and Chemotherapy












require at least 7 days of incubation, and ertapenem was shown to degrade at rates of
more than 20-fold the doubling time of M. tuberculosis under the acidic incubation
conditions, which causes the results to show resistance even though this is not the case
(14).
Although intramuscular injection can be preferred in settings with limited resources,
in our setting it is not licensed and therefore not recommended. A previous study
showed that 1,000 mg intramuscularly injected ertapenem had an AUC0–∞ similar to
that of a 30-min intravenous infusion of 1,000 mg ertapenem (541.8 versus 597.4 g ·
h/ml), as well as a similar renal clearance (10.9 versus 12.7 ml/min) and the same
half-life of 3.8 h (25). The only signiﬁcantly different PK parameter between intravenous
and intramuscular injection was shown to be the Cmax (25). However, it remains to be
seen whether a 2,000-mg intramuscular injection can be administered or should be
given as two separate injections. A study is needed to speciﬁcally address the possibility
of the intramuscular administration of 2,000 mg ertapenem.
In conclusion, 2,000 mg ertapenem once daily in TB patients reached f40% TMIC
in most patients. Therefore, this dose is suitable for examination in a phase 2 study to
test its efﬁcacy and tolerability. This study shows promise for the use of 2,000 mg
ertapenem as an option in the treatment of MDR- and XDR-TB.
MATERIALS AND METHODS
Ethics. This prospective pharmacokinetic study was conducted at the Tuberculosis Center Beat-
rixoord of the University Medical Center Groningen (Haren, The Netherlands). The study was approved
by the Medical Ethical Review Board of the University Medical Center Groningen (METc; M16.200922).
Written informed consent was obtained from all subjects included in this study.
Inclusion and exclusion criteria. We planned to enroll 12 patients between 18 and 64 years of age
with drug-susceptible TB. The M. tuberculosis isolate (including M. africanum) should be drug susceptible,
either proven by culture or conﬁrmed with molecular testing. Patients were excluded if they had a
previous anaphylactic reaction to ertapenem or another -lactam antibiotic, renal insufﬁciency (esti-
mated glomerular ﬁltration rate [eGFR] of 30 ml/min), pregnancy, HIV infection, and/or a body weight
of 40 kg or less.
Sampling. Ertapenem was administered as a single intravenous infusion of 2,000 mg ertapenem in
30 min. Blood samples (2 ml) were collected at 0, 0.5, 1, 2, 3, 4, 8, 12, and 24 h postinfusion. During plasma
sampling patients were on a continuous saline drip. Plasma samples were stored at 80°C until analysis.
A validated liquid chromatography-tandem mass spectrometry method was used to determine the total
ertapenem concentration in plasma (26).
Pharmacokinetics. The area under the concentration-time curve up to 24 h after infusion (AUC0–24)
was determined with a two-compartment pharmacokinetic method using the KINFIT module of
MWPharm 3.82 (Mediware, Zuidhorn, The Netherlands).
Determination of the T>MIC of the unbound fraction. The concentration-time curve of each
patient was used to determine whether the f40% TMIC is reached with a single intravenous infusion
of 2,000 mg ertapenem. For this simulation, we plotted MIC distributions from 0 to 64 mg/liter, for which
the amount of time that the concentration-time curve is above the MIC was determined. Since there are
no clinical breakpoints available for ertapenem in the treatment ofM. tuberculosis, the PK/PD breakpoints
of ertapenem were used as recommended by EUCAST. These PK/PD breakpoints are set by EUCAST and
are derived from the relationship between the PK/PD index and the MIC for other bacteria by using
Monte Carlo simulations and the variability in both exposure and MIC (27, 28). Additionally, the results
were discussed for the f40% TMIC at a MIC of 2.0 mg/liter, as this was shown to be a more accurate
MIC for ertapenem based on hollow-ﬁber study results (13). The percentage of unbound ertapenem used
for this study was 5% (4, 18). The percentage of unbound ertapenem increases disproportionately with
doses above 2,000 mg, when total drug concentrations are higher than 150 mg/liter (7). However, we
consider the worst-case scenario of 5% unbound ertapenem at all plasma concentrations. The target
value of TMIC was 40% (i.e., 9.6 h). The f40% TMIC was calculated by multiplying the plasma
concentration by 20, because of the 5% protein binding, to get the target MIC. The curve then was
plotted with MW/Pharm 3.82 (Mediware, Zuidhorn, The Netherlands), from which we could see how long
the curve exceeded the target MIC.
Statistics. Statistical analysis of patient characteristics in studies with ertapenem compared with
those from our study was performed using Analyze-it for Microsoft Excel, version 2.30. Patient charac-
teristics and PK parameters were compared using Mann-Whitney U test for age, BMI, body surface area
(BSA), serum creatinine levels at baseline, and dose/total bodyweight. The different groups were
compared using Fisher’s exact test for sex and Pearson’s chi-square test for ethnicity.
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